Altered prefrontal dopaminergic function in chronic recreational ketamine users

American Journal of Psychiatry

Volumn 162, Issue 12, 2005, Pages 2352-2359

  Narendran, Rajesh ^a   Gordon Frankle, W ^b   Keefe, Richard ^b   Gil, Roberto ^b   Martinez, Diana ^b   Slifstein, Mark ^b   Kegeles, Lawrence S ^b   Talbot, Peter S ^b   Huang, Yiyun ^b   Hwang, Dah Ren ^b   Khenissi, Leyla ^b   Cooper, Thomas B ^b   Laruelle, Marc ^b   Abi Dargham, Anissa ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; CARBON 11; DOPAMINE; DOPAMINE 1 RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RADIOLIGAND; RECREATIONAL DRUG;

ADDICTION; ADULT; ARTICLE; BINDING COMPETITION; BINDING KINETICS; BRAIN CORTEX; BRAIN FUNCTION; CLINICAL ARTICLE; DRUG BRAIN LEVEL; DRUG USE; FEMALE; HAIR ANALYSIS; HUMAN; LIMBIC CORTEX; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRIATE CORTEX; WORKING MEMORY;

ADULT; ANALGESICS; BENZAZEPINES; BENZOFURANS; CARBON RADIOISOTOPES; DOPAMINE; FEMALE; FUNCTIONAL LATERALITY; HAIR; HUMANS; KETAMINE; MALE; MEMORY; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TISSUE DISTRIBUTION; UP-REGULATION;

EID: 28444468469     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.12.2352     Document Type: Article

References (40)

1. Anis NA, Berry SC, Burton NR, Lodge D: The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79:565-575
2. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76:5372-5376
3. Mattison AM, Ross MW, Wolfson T, Franklin D: Circuit party attendance, club drug use, and unsafe sex in gay men. J Subst Abuse 2001; 13:119-126
4. Ross MW, Mattison AM, Franklin DR Jr: Club drugs and sex on drugs are associated with different motivations for gay circuit party attendance in men. Subst Use Misuse 2003; 38:1173-1183
5. Freese TE, Miotto K, Reback CJ: The effects and consequences of selected club drugs. J Subst Abuse Treat 2002; 23:151-156
6. Hansen G, Jensen SB, Chandresh L, Hilden T: The psychotropic effect of ketamine. J Psychoactive Drugs 1988; 20:419-25
7. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers M Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214
8. Jansen KL: A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 2000; 32:419-433
9. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A: NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14:301-307
10. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57:270-276
11. Allen RM, Young SJ: Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135:1081-1084
12. Curran HV, Morgan C: Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000; 95:575-590
13. Curran HV, Monaghan L: In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001; 96:749-760
14. Jentsch JD, Roth RH: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20:201-225
15. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS: Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205:929-932
16. Deuten AY, Tam SY, Freeman AS, Bowers MB Jr, Roth RH: Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 1987; 134:257-264
17. Carlezon WA Jr, Wise RA: Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 1996; 16:3112-3122
18. Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, Uchimura H, Tashiro N: Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 1994; 633:337-342
19. Verma A, Moghaddam B: NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 1996; 16:373-379
20. Kakiuchi T, Nishiyama S, Sato K, Ohba H, Nakanishi S, Tsukada H: Effect of MK801 on dopamine parameters in the monkey brain. Neuroimage 2001; 16:110
21. 1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 2003; 28:1703-1711
22. 1 receptors and working memory in schizophrenia. J Neurosci 2002; 22:3708-3719
23. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308
24. Moghaddam B: Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40:881-884
25. Tsai G, Coyle JT: Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42:165-179
26. 1-dopamine receptors. J Nucl Med 1998; 39:2061-2068
27. 11C]NNC 112 in humans: validation and reproducibility J Cereb Blood Flow Metab 2000; 20:225-243
28. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M: Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23:285-300
29. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ: Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6:279-287
30. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frakowiak RSJ: Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2:189-210
31. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD: Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996; 4(3, part 1):223-235
32. Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC: Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapp 1994; 1:293-304
33. Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M: Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003; 29:45-55
34. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA: Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6:869-872
35. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D: Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154:805-811
36. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J: Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7:9-24
37. Carr DB, Sesack SR: Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000; 20:3864-3873
38. Weinberger DR: Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660-669
39. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
40. Laruelle M, Kegeles LS, Abi-Dargham A: Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 2003; 1003:138-158